CME Group Inc.
CME
$0.00
+2.75%
CME Group operates major exchanges for trading futures and derivatives across interest rates, equity indexes, currencies, energy, metals, and commodities. It is a dominant global financial infrastructure provider, leveraging its scale, diverse product suite, and strategic acquisitions to maintain a leading position.…
CME
CME Group Inc.
$0.00
Related headlines
Investment Opinion: Should I buy CME Today?
Based on a synthesis of the data, CME Group presents a high-quality, low-risk business trading at a full valuation. Its exceptional profitability, financial health, and shareholder returns are compelling. However, the current price reflects these strengths, offering limited margin of safety. The recent underperformance and lack of clear near-term catalysts suggest patience is warranted. Therefore, the Synthesized Analyst Rating is Hold. Investors seeking a stable, blue-chip financial infrastructure stock may find it suitable for a core portfolio position, but those seeking significant capital appreciation may want to wait for a more attractive entry point.
Sign up to view all
CME 12-Month Price Forecast
The AI assessment is neutral based on the offsetting forces of stellar fundamentals and full valuation. The high probability is assigned to a base case of range-bound trading, with a bullish case dependent on external catalysts and a bearish case limited by the company's robust financial position.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CME Group Inc.'s 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
3 analysts
Implied Upside
—
vs. current price
Analyst Count
3
covering this stock
Price Range
$0 - $0
Analyst target range
No sufficient analyst coverage available. The provided data includes recent institutional rating actions from firms like Morgan Stanley (Overweight), TD Cowen (Buy), and Barclays (Equal Weight), but does not contain a consensus target price or a comprehensive ratings distribution from a broad analyst pool.
Bulls vs Bears: CME Investment Factors
CME Group is a financially fortress-like company with a dominant, profitable business model. However, its stock carries a premium valuation and faces headwinds from recent market weakness and macroeconomic sensitivity. The balance of strengths and weaknesses suggests a stable but fully-valued investment.
Bullish
- Dominant Market Position: Operates major global exchanges with a diverse, high-margin product suite.
- Exceptional Financial Health: Very low debt (D/E 0.13), massive liquidity (Current Ratio 93.0), and strong cash flow.
- Robust Profitability: Net income margin of 70.8% in Q4 2025, driven by high operating leverage.
- Beneficiary of Market Volatility: Trading activity and revenue often increase during periods of economic uncertainty.
Bearish
- Premium Valuation: High P/E (24.3), P/S (15.1), and EV/EBITDA (17.1) multiples limit upside.
- Interest Rate Sensitivity: Prolonged high rates could pressure growth and certain asset classes it serves.
- Recent Price Weakness: Stock down 7.56% in past month, underperforming the S&P 500.
- Regulatory and Political Risk: Operates in a heavily regulated industry susceptible to policy changes.
CME Technical Analysis
The stock has shown strong overall performance over the past six months, rising 11.27% from its price around $265 in early October 2025 to $295.35 as of March 31, 2026. This uptrend was particularly pronounced from late January through late February 2026, where the price climbed from the $280s to a peak above $326. Short-term performance has been more volatile and negative recently. Over the past month, the stock declined 7.56%, underperforming the S&P 500 (SPY) which fell 5.25%, resulting in a negative 1-month relative strength of -2.31. However, over the past three months, it gained 8.16%, significantly outperforming the SPY's decline of 4.63%, with a strong relative strength of 12.79. The current price of $295.35 sits roughly in the middle of its 52-week range, positioned about 10.2% below its 52-week high of $329.16 and about 18.8% above its 52-week low of $248.53. The stock's beta of 0.26 indicates it has been much less volatile than the broader market during this period.
Beta
0.30
0.30x market volatility
Max Drawdown
-11.0%
Largest decline past year
52-Week Range
$249-$329
Price range past year
Annual Return
+16.2%
Cumulative gain past year
| Period | CME Return | S&P 500 |
|---|---|---|
| 1m | -6.2% | -4.3% |
| 3m | +13.1% | -4.0% |
| 6m | +15.3% | -2.0% |
| 1y | +16.2% | +22.2% |
| ytd | +13.1% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CME Fundamental Analysis
Revenue for Q4 2025 was $1.65 billion, representing a year-over-year growth of 8.1% from Q4 2024. Profitability remains robust, with a net income margin of 70.8% for the quarter, significantly higher than the 57.3% margin in the year-ago period, driven by strong operating leverage and high gross margins above 85%. The company exhibits exceptional financial health with a very low debt-to-equity ratio of 0.13 and an extremely high current ratio of 93.0, indicating minimal leverage and massive liquidity. Free cash flow generation is strong, with trailing twelve-month free cash flow of $4.19 billion, supporting substantial shareholder returns via dividends and buybacks. Operational efficiency is highlighted by a strong return on equity (ROE) of 14.1%. The company's business model, centered on clearing and transaction fees, generates high-margin, recurring revenue with significant operating leverage, contributing to its superior profitability metrics.
Quarterly Revenue
$1.6B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$4.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CME Overvalued?
Given the company's consistently positive and substantial net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is 24.3, while the forward P/E is 23.2, suggesting the market is pricing in stable earnings growth. The PEG ratio of 1.58, based on trailing earnings, indicates the stock may be fairly valued relative to its growth prospects. Peer comparison data is not available in the provided valuation inputs. However, the company's valuation multiples, such as its Price-to-Sales ratio of 15.1 and EV-to-EBITDA of 17.1, reflect its premium business model characterized by high margins, strong cash flow, and a dominant market position in financial exchanges.
PE
24.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 19x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.1x
Enterprise Value Multiple
Investment Risk Disclosure
CME's primary risks are macroeconomic and valuation-based. The company's revenue is tied to trading volumes, which are sensitive to interest rate expectations and market volatility. Recent news highlights the Federal Reserve's commitment to fighting inflation, which could sustain higher rates and potentially dampen activity in some asset classes. While CME often benefits from uncertainty, a prolonged economic slowdown could reduce overall trading.
Operationally, the company faces constant regulatory scrutiny and potential political interference, as it is a critical piece of financial infrastructure. Its exceptionally high valuation multiples (P/E ~24, P/S ~15) pose a significant risk if earnings growth fails to meet expectations or if there is a market-wide derating of premium stocks. The stock's recent 7.56% decline over the past month, underperforming the market, may indicate these concerns are being priced in.
Despite these risks, the company's fundamental risk is mitigated by its unparalleled financial strength, with minimal debt and enormous liquidity, providing a large buffer against downturns. The business model itself carries low credit and counterparty risk due to its clearinghouse function.
FAQ
The key risks are valuation compression and macroeconomic sensitivity. The stock's high multiples could contract if growth slows. Its revenue is linked to trading volumes, which can decline in stable or recessionary markets. Regulatory changes pose a constant, though manageable, threat. Finally, the stock has shown recent weakness, falling 7.56% in the past month, indicating potential near-term downward pressure.
The 12-month outlook is for range-bound trading with a neutral bias. The base case (60% probability) sees the stock between $290 and $325, reflecting stable earnings. A bull case (25%) could see a retest of the $329 high and beyond on strong catalysts. A bear case (15%) could see a pullback toward the $248 low on a growth scare. The AI assessment is neutral with medium confidence, given the balance of strong fundamentals and full valuation.
CME stock appears fairly valued to slightly overvalued based on traditional metrics. Its trailing P/E of 24.3 and Price-to-Sales ratio of 15.1 are high, reflecting its premium business model and margins. The PEG ratio of 1.58 suggests the stock is priced appropriately relative to its growth. While not egregiously expensive, these multiples leave little room for error and imply that future returns will be driven more by earnings growth than multiple expansion.
CME is a high-quality stock but not an obvious buy at current levels. Its exceptional fundamentals, including a 70.8% net income margin and $4.19B in annual free cash flow, make it a strong company. However, with a trailing P/E of 24.3 and forward P/E of 23.2, the stock is fully valued. It is best suited for investors seeking a stable, low-beta holding for the long term, rather than those looking for near-term capital appreciation.
CME is far more suitable for a long-term investment horizon. Its low beta of 0.26 indicates low correlation with short-term market swings, making it a poor candidate for short-term trading. As a long-term holding, investors can benefit from the company's durable competitive advantages, high cash generation, and consistent shareholder returns through dividends and buybacks, allowing for compounding over time.